Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, announced the pricing of its underwritten public offering of 4,225,352 American Depositary Shares (“ADSs”), which will raise gross proceeds of approximately $600M.
Latham & Watkins LLP represented Ascendis Pharma A/S in the transaction with a corporate team led by Silicon Valley partner Mark Roeder with associates John Williams, Traci Biedermann, Tess Bloom, and Christopher Lim. Advice was also provided on compensation and benefits matters by Los Angeles partner Sam Weiner with associate Janet Hsu; on tax matters by Silicon Valley partner Jay Metz with associate Lilly Fang; on intellectual property matters by Silicon Valley partner Judith Hasko with associate Gavin Liu; on FDA regulatory matters by Washington DC partner Ben Haas and Brussels partner Hector Armengod with San Francisco counsel Betty Pang and associates Chad Jennings and Lacey Henry.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
